MYCN amplification was identified as the first independent prognostic factor indicating adverse clinical outcomes in neuroblastomas [13, 14], which is observed in approximately 20% of cases [15] and accounts for about 40% of high-risk neuroblastomas [16]. This evidence concerns the gene MYCN and neuroblastoma.